PDCD1 and melanoma: The use of anti-programmed cell death-1 (PD-1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) antibodies in combination therapy for melanoma patients has achieved prolonged patient survival,1 led to approval by the U.S. Food and Drug Administration (FDA).